source
- uniQure shares tumble 41% after Huntington’s gene therapy misses primary endpointuniQure reported updated 48‑month data from its phase 1/2 trial of AMT‑130 in Huntington’s disease. The therapy showed a 44% slowing of disease progression on the composite Unified Huntington’s Dis…
- Ontario launches $5M QuickStart program to cut clinical trial start-up time to 45 daysOntario’s Clinical Trials Ontario has introduced a $5 million QuickStart program that promises to reduce the time needed to launch a clinical trial to as little as 45 days. The initiative is desig…